Replies to post #46531 on Avid Bioservices Inc (CDMO)

[MobyInvestor]

r62etc: interesting stuff. Amy Brideau-Andersen

I believe 'r' was referring to the fact that Dr. Brideau-Andersen worked for Valeant Pharmaceuticals, the same company that was awarded the contract that he mentioned in:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45147789

Regards,

moby

[cheynew]

Entdoc,your post from back in January:
"r62etc: interesting stuff. Amy Brideau-Andersen, PPHM's new director of a new PPHM Anti-Viral Research Group sounds like the real thing. Her experience with viral hemorrhagic fever is a direct hit. The literature on PS has exploded, and PPHM is responding appropriately as a leader in clinical application of the principles. Anti-PS fixes the apoptotic glitch in cancer and/or virally infected cells, and unblocking the body's potential immunological ability to delete unwanted "immortal cells and parasites. The strange thing is that Bavi is also capable of transporting a payload to the problem area, a traditional treatment d'jour."

Dr. Brideau-Andersen is apparently no longer with PPHM. Short stay, wonder why she left. What does that say about PPHM's anti-viral program? Her linked in profile:

Amy Brideau-Andersen
Associate Director at Perseid Therapeutics (Perseid Therapeutics was formed as a joint venture between Maxygen and Astellas and Amy worked a Maxygen previously)

Location
San Francisco Bay Area
Industry
Pharmaceuticals
Current •Associate Director at Perseid Therapeutics
Past •Associate Director, Infectious Diseases; Sr. Manager, Virology at Peregrine Pharmaceuticals [color=red][/color]•Principal Scientist at Valeant Pharmaceuticals
•Staff Scientist at Maxygen
Post doctoral fellow at The Scripps Research Institute see less...

see all...
Education •Princeton University
•Worcester Polytechnic Institute